drugset / Trial / NCT01548560

Assessing the Safety of Dapivirine Gel and Film Formulations

NCT01548560

Phase 1 Completed 60 enrolled International Partnership for Microbicides, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.

Timeline

Start
2012-08
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject dapivirine Small molecule 0.5 % Other
Subject dapivirine Small molecule 1.25 mg Other
Subject dapivirine Small molecule 2.5 g Other